Camp4 Therapeutics Reports Positive Preclinical Data for Lead Candidate CMP-002 in SYNGAP1-Related Disorder

summarizeSummary

Camp4 Therapeutics released positive preclinical data for CMP-002, demonstrating improved seizure control in a SYNGAP1-related disorder model, paving the way for a Phase 1/2 clinical trial in 2H 2026.

check_boxKey Events

• Positive Preclinical Data for CMP-002

  New data shows CMP-002 significantly improved seizure threshold and severity in a SYNGAP1 haploinsufficient mouse model.

• Advancing Lead Candidate to Clinic

  The company plans to initiate a Phase 1/2 clinical trial for CMP-002 in individuals with SYNGAP1-related disorder in the second half of 2026.

• Addressing High Unmet Need

  CMP-002 targets SYNGAP1-related disorder, a rare CNS condition with no approved disease-modifying therapies, affecting over 10,000 individuals in the US.

auto_awesomeAnalysis

Camp4 Therapeutics announced new preclinical data showing its lead therapeutic candidate, CMP-002, significantly improved seizure outcomes in a model of SYNGAP1-related disorder. This strengthens the scientific basis for CMP-002 and supports the company's plan to initiate a Phase 1/2 clinical trial in the second half of 2026, addressing a rare CNS disorder with high unmet medical need.